Pexidartinib is primarily used in the treatment of tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that affects joints and tendons. It is particularly effective for patients where surgery is not a viable option due to the tumor's location or potential complications. The drug works by inhibiting specific receptors involved in the growth and survival of tumor cells, helping to reduce tumor size and alleviate symptoms such as pain and stiffness.

In clinical settings, it is administered orally, making it a convenient option for long-term management of the condition. However, its use is closely monitored due to potential side effects, including liver toxicity. Regular liver function tests are recommended during treatment to ensure patient safety.

Pexidartinib represents a significant advancement in targeted therapy for TGCT, offering a non-surgical alternative for patients with limited treatment options. Its approval has provided hope for improved quality of life for those affected by this challenging condition.